New and emerging therapies for asthma

Annals of Allergy, Asthma & Immunology

January 2016 Volume 116, Issue 1, Pages 14-17  MOC-CME Review

Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Planning Committee Members:
Taylor Doherty, MD (Author)
Jonathan A. Bernstein, MD (Annals CME Subcommittee)
Guha Krishnaswamy, MD (Annals CME Subcommittee)
John J. Oppenheimer, MD (Annals CME Subcommittee, Associate Editor)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)

Target Audience

Physicians involved in providing patient care in the field of allergy/asthma/immunology

Learning Objectives

At the conclusion of this activity, participants should be able to:
Describe the biomarkers associated with type 2 or TH2 asthma
Identify novel biologic agents for asthma and the molecules targeted by such agents and discuss the key outcomes of clinical trials with these agents

Additional information
Disclosure: 

M.H. Grayson has received research grants from Children’s Research Institute/Children’s Hospital of Wisconsin, Merck, National Institutes of Health (NIH), and Polyphor. G.D. Marshall has received research grants from Amgen, AstraZeneca, Health Resources and Services Administration (HRSA) and National Institutes of Health (NIH). J.J. Oppenheimer has been a consultant/advisor for AstraZeneca, GlaxoSmithKline, Meda, Mylan, and Sunovion; has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis. J.A. Bernstein, T.A. Doherty, A.S. Kim and G. Krishnaswamy have no relevant financial relationships to disclose. Reviewers and Education/Editorial staff have no relevant financial relationships to disclose. Any unapproved/investigative uses of therapeutic agents/devices discussed are appropriately noted.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC
Course opens: 
01/01/2016
Course expires: 
12/31/2017
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 MOC

Accreditation Period

Course opens: 
01/01/2016
Course expires: 
12/31/2017

Price

Cost:
$0.00
Please login or create an account to take this course.